RecruitingPHASE1, PHASE2NCT06239272
NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
Studying Angiomatoid fibrous histiocytoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- St. Jude Children's Research Hospital
- Principal Investigator
- Jessica Gartrell, MD, MDSt. Jude Children's Research Hospital
- Intervention
- Surgical resection(procedure)
- Enrollment
- 139 enrolled
- Eligibility
- 30 years · All sexes
- Timeline
- 2024 – 2037
Study locations (6)
- Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
- Our Lady of the Lake Children's Hospital, Baton Rouge, Louisiana, United States
- Dana Farber Cancer Institute, Boston, Massachusetts, United States
- Washington University Medical Center, St Louis, Missouri, United States
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
- St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06239272 on ClinicalTrials.gov